Drugs / Globo-H-GM2-sTn-TF-Tn-KLH conjugate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01248273 | Nov 2010 → Mar 2017 | fallopian tube disorder, ovarian cancer, peritoneum cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Globo-H-GM2-sTn-TF-Tn-KLH conjugate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01248273 ↗ |
| Modality | Vaccine | “This trial will investigate the safety and immune responses following immunization with the unimolecular pentavalent Globo-H-GM2-sTn-TF-Tn-KLH conjugate” NCT01248273 ↗ |
| Route | Subcutaneous | “The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19” NCT01248273 ↗ |